1. Search Result
Search Result
Isoforms Recommended: DDR1
Results for "

DDR1

" in MedChemExpress (MCE) Product Catalog:

45

Inhibitors & Agonists

2

Biochemical Assay Reagents

2

Inhibitory Antibodies

11

Recombinant Proteins

2

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13979
    DDR1-IN-1
    5 Publications Verification

    Discoidin Domain Receptor Cancer
    DDR1-IN-1 is a potent and selective DDR1 receptor tyrosine kinase inhibitor with an IC50 of 105 nM; 4-fold less potent for DDR2 (IC50 = 413 nM) [1].
    DDR1-IN-1
  • HY-16961
    Sitravatinib
    Maximum Cited Publications
    6 Publications Verification

    MGCD516; MG-516

    VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor Inflammation/Immunology Cancer
    Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively [1]. Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .
    Sitravatinib
  • HY-U00444
    7rh
    Maximum Cited Publications
    6 Publications Verification

    DDR1-IN-2

    Discoidin Domain Receptor Inflammation/Immunology
    7rh (DDR1-IN-2) is a potent inhibitor of discoidin domain receptor 1 (DDR1), with an IC50 of 13.1 nM, and also less potently inhibits DDR2, with an IC50 of 203 nM. 7rh is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    7rh
  • HY-15514
    Merestinib
    Maximum Cited Publications
    6 Publications Verification

    LY2801653

    c-Met/HGFR FLT3 ROS Kinase Discoidin Domain Receptor Cancer
    Merestinib (LY2801653) is a potent, orally bioavailable c-Met inhibitor (Ki=2 nM) with anti-tumor activities. Merestinib (LY2801653) also has potent activity against MST1R (IC50=11 nM), FLT3 (IC50=7 nM), AXL (IC50=2 nM), MERTK (IC50=10 nM), TEK (IC50=63 nM), ROS1, DDR1/2 (IC50=0.1/7 nM) and MKNK1/2 (IC50=7 nM) [1] .
    Merestinib
  • HY-135401
    VU6015929
    1 Publications Verification

    Discoidin Domain Receptor Inflammation/Immunology
    VU6015929 is a potent, selective and orally active dual discoidin domain receptor 1/2 (DDR1/2) inhibitor with IC50s of 4.67 nM and 7.39 nM, respectively. VU6015929 potently blocks collagen-induced DDR1 activation and collagen-IV production [1].
    VU6015929
  • HY-100115
    TA-02
    2 Publications Verification

    p38 MAPK Autophagy Cardiovascular Disease Inflammation/Immunology Cancer
    TA-02, an analog of SB 203580 (HY-10256), is a p38 MAPK inhibitor with an IC50 of 20 nM. TA-02 especially inhibits TGFBR-2. TA-02 exhibits similar cardiogenic properties as SB 203580 and SB 202190 (HY-10295) [1].
    TA-02
  • HY-133669

    Discoidin Domain Receptor Cancer
    DDR1-IN-5 is a selective Discoidin Domain Receptor family, member 1 (DDR1) inhibitor with an IC50 of 7.36 nM. DDR1-IN-5 inhibits auto-phosphorylation DDR1b (Y513) with an IC50 of 4.1 nM. DDR1-IN-5 has anti-cancer activity [1]. DDR1-IN-5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    DDR1-IN-5
  • HY-133670

    Discoidin Domain Receptor Cancer
    DDR1-IN-6 is a selective Discoidin Domain Receptor family, member 1 (DDR1) inhibitor with an IC50 of 9.72 nM. DDR1-IN-6 inhibits auto-phosphorylation DDR1b (Y513) with an IC50 of 9.7 nM. DDR1-IN-6 has anti-cancer activity [1]. DDR1-IN-6 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    DDR1-IN-6
  • HY-114173

    Discoidin Domain Receptor Inflammation/Immunology
    DDR1-IN-4 (Compound 2.45) is a selective and potent Discoidin Domain Receptor 1 (DDR1) autophosphorylation inhibitor, with IC50 values of 29 nM and 1.9 μM for DDR1 and DDR2, respectively [1].
    DDR1-IN-4
  • HY-176184

    PROTACs Discoidin Domain Receptor Cancer
    PROTAC DDR1 degrader-1 is a PROTAC based DDR1 degrader (Red: DDR1 inhibitor (HY-176185), black: linker, Blue: E3 ligase ligand) [1].
    PROTAC DDR1 degrader-1
  • HY-NP175

    Biochemical Assay Reagents Integrin Discoidin Domain Receptor Others
    Collagen (bovine skin) is a three-dimensional cell culture matrix and morphoregulator extracted from bovine skin, which binds to integrins (such as α1β1, α2β1, α11β1) and discoidin domain receptors (DDR1 and DDR2). Collagen (bovine skin) can be reconstituted into a three-dimensional fibrous network to mimic the in vivo tissue environment. It can not only be modified through cross-linking or concentration adjustment, but also interact with fibronectin to enhance matrix-associated cellular activities. Collagen (bovine skin) mediates the proliferation, aggregation, durotactic migration and differentiation of fibroblasts, regulates the synthesis, remodeling and contraction of extracellular matrix, and modulates the expression, activation of MMP as well as cell apoptosis, etc. Collagen (bovine skin) can be used in studies related to the mechanisms of cancer occurrence and development [1] .
    Collagen (bovine skin)
  • HY-RS03621

    Small Interfering RNA (siRNA) Discoidin Domain Receptor Others

    Ddr1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ddr1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ddr1 Mouse Pre-designed siRNA Set A
    Ddr1 Mouse Pre-designed siRNA Set A
  • HY-RS03620

    Small Interfering RNA (siRNA) Discoidin Domain Receptor Others

    DDR1 Human Pre-designed siRNA Set A contains three designed siRNAs for DDR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    DDR1 Human Pre-designed siRNA Set A
    DDR1 Human Pre-designed siRNA Set A
  • HY-15514A
    Merestinib dihydrochloride
    Maximum Cited Publications
    6 Publications Verification

    LY2801653 dihydrochloride

    c-Met/HGFR FLT3 ROS Kinase Discoidin Domain Receptor Cancer
    Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailable c-Met inhibitor (Ki=2 nM) with anti-tumor activities. Merestinib dihydrochloride also has potent activity against MST1R (IC50=11 nM), FLT3 (IC50=7 nM), AXL (IC50=2 nM), MERTK (IC50=10 nM), TEK (IC50=63 nM), ROS1, DDR1/2 (IC50=0.1/7 nM) and MKNK1/2 (IC50=7 nM) [1] .
    Merestinib dihydrochloride
  • HY-162540

    ATTECs Discoidin Domain Receptor Cancer
    LLC355 is a discoidin domain receptor 1 (DDR1) ATTEC degrader. LLC355 efficiently degrades DDR1 protein with a DC50 value of 150.8 nM in non-small cell lung cancer NCI-H23 cells. LLC355 induces DDR1 degradation via lysosome-mediated autophagy. LLC355 potently inhibits cancer cell tumorigenicity, migration, and invasion [1].
    LLC355
  • HY-W018931

    Discoidin Domain Receptor Cancer
    DDR Inhibitor is a potent discoidin domain receptor (DDR) inhibitor, with an IC50 of 3.3 nM for DDR2, and shows 53% inhibition on DDR1 at 1.5 nM.
    DDR Inhibitor
  • HY-156552

    Discoidin Domain Receptor Inflammation/Immunology Cancer
    DDR1/2 inhibitor-2 (Example 31) is a DDR1/DDR2 inhibitor, with IC50 values less than 100 nM. DDR1/2 inhibitor-2 can be used for research of cancer and fibrotic diseases [1].
    DDR1/2 inhibitor-2
  • HY-13979A
    DDR1-IN-1 dihydrochloride
    5 Publications Verification

    Discoidin Domain Receptor Cancer
    DDR1-IN-1 dihydrochloride is a potent and selective DDR1 receptor tyrosine kinase inhibitor with an IC50 of 105 nM; 4-fold less potent for DDR2 (IC50 = 413 nM) [1].
    DDR1-IN-1 dihydrochloride
  • HY-100695

    Discoidin Domain Receptor Cancer
    DDR-TRK-1, a chemical probe, is a selective Discoidin Domain Receptor 1 (DDR1) inhibitor, with an IC50 value of 9.4 nM. DDR-TRK-1 also inhibits TRK family.
    DDR-TRK-1
  • HY-167745

    Discoidin Domain Receptor Neurological Disease
    DDR1-IN-9 is a selective inhibitor of DDR1 with significant kinase activity suppression, exhibiting a Kd value of 4.7 nM and an IC50 value of 9.4 nM. DDR1-IN-9 demonstrates reduced potency against a diverse panel of 400 nonmutated kinases, indicating its specificity. Additionally, DDR1-IN-9 shows favorable pharmacokinetic properties and potential therapeutic effects in a model of pulmonary fibrosis.
    DDR1-IN-9
  • HY-167208

    Discoidin Domain Receptor p38 MAPK Inflammation/Immunology Cancer
    SR-302, a chemical probe, is a potent and selectivity DDR/p38 inhibitor, with IC50 values of 0.125, 0.023 and 0.018 μM for p38α, DDR1 and DDR2, respectively. SR-302 can be used for the research of fibrotic disorders, such as renal and pulmonary fibrosis, atherosclerosis, and various forms of cancer [1].
    SR-302
  • HY-176185

    Ligands for Target Protein for PROTAC Cancer
    DDR1 ligand 1 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). DDR1 ligand 1 can be used for the synthesis of PROTAC DDR1 degrader-1 (HY-176184) [1].
    DDR1 ligand 1
  • HY-15814

    Bcr-Abl PDGFR c-Kit Src JAK Apoptosis Cancer
    HG-7-85-01 is a type II ATP competitive inhibitor of wild-type and gatekeeper mutations forms of Bcr-Abl, PDGFRα, Kit, and Src kinases. HG-7-85-01 inhibits T315I mutant Bcr-Abl kinase, KDR and RET with IC50s of 3 nM, 20 nM and 30 nM, and is only weak or no inhibition of other kinases (IC50>2 μM). HG-7-85-01 inhibits the cell proliferation, which is mediated by the induction of apoptosis, and inhibition of cell-cycle progression [1].
    HG-7-85-01
  • HY-176187

    Target Protein Ligand-Linker Conjugates Cancer
    DDR1 ligand 1-piperidine is a target protein ligand and linker conjugate, which can be used for the synthesis of PROTAC DDR1 degrader-1 (HY-176184) [1].
    DDR1 ligand 1-piperidine
  • HY-173284

    Discoidin Domain Receptor Cancer
    DDR1-IN-11 (Compound 4) is an inhibitor of Discoidin domain receptor 1 (DDR1) with an IC50 of 46.16 nM. DDR1-IN-11 can achieve an inhibition rate of 99.86% against Z-138 cells at a concentration of 10 μM, and it can be used in the research of acute myeloid leukemia (AML) [1].
    DDR1-IN-11
  • HY-NP131

    Discoidin Domain Receptor Apoptosis Autophagy Cancer
    Recombinant Humanized Type III Collagen 10.4kDa is a novel biomaterial that have anticancer effects. Recombinant Humanized Type III Collagen 10.4kDa activates discoidin domain receptor 1 (DDR1), and thus inhibits autophagy, proliferation, and migration of cancer cells, and induces apoptosis [1].
    Recombinant Humanized Type III Collagen (10.4kDa)
  • HY-176849

    Discoidin Domain Receptor Cancer
    DDR2-IN-2 is a Discoidin domain receptor 2 (DDR2) inhibitor. DDR2-IN-2 can be used for the research of cancer [1].
    DDR2-IN-2
  • HY-149591

    TGF-β Receptor Anaplastic lymphoma kinase (ALK) Cancer
    M4K-2009 is an orally bioactive ALK2 inhibitor with an IC50 of 13 nM. M4K-2009 exerts comparable inhibitory potency against wild-type and mutant ALK2 G328V, ALK2 R206H, and ALK2 R258G. M4K-2009 exhibits moderate off-target inhibitory activity against hERG potassium channels. M4K-2009 can be used in studies related to diffuse intrinsic pontine glioma [1] .
    M4K-2009
  • HY-169741

    Discoidin Domain Receptor Cancer
    DDR1-IN-10 (compound 7q) is a DDR1 inhibitor. DDR1-IN-10 can be used in the study of pancreatic cancer, non-small cell lung cancer, and gastric carcinoma [1].
    DDR1-IN-10
  • HY-RS03622

    Small Interfering RNA (siRNA) Others

    Ddr1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ddr1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ddr1 Rat Pre-designed siRNA Set A
    Ddr1 Rat Pre-designed siRNA Set A
  • HY-162102

    Discoidin Domain Receptor Cancer
    DDR1-IN-8 (compound 7s) is a potent inhibitor of DDR1/2, with the IC50 values of 0.045 μM and 0.126 μM, respectively. DDR1-IN-8 has anti-tumor activity [1].
    DDR1-IN-8
  • HY-16961A

    MGCD516 malate; MG-516 malate

    VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor Inflammation/Immunology Cancer
    Sitravatinib malate (MGCD516 malate) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively [1]. Sitravatinib malate shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .
    Sitravatinib malate
  • HY-175281

    PROTACs Src Discoidin Domain Receptor Bcr-Abl Apoptosis Cancer
    SJ11646 is a Dasatinib (HY-10181)-based LCK PROTAC degrader with a DC50 of 0.00838 pM. SJ11646 has potent cytotoxicity against LCK-activated T-cell acute lymphoblastic leukemia (T-ALL) cells and primary leukemia samples with drastically prolonged suppression of LCK signaling, and induces T-ALL apoptosis. SJ11646 binds to 51 human kinases with a high affinity (particularly ABL1, KIT, and DDR1). SJ11646 has superior antileukemic efficacy in T-ALL mice model. [1] . Pink: LCK ligand (HY-107447); Blue: CRBN ligase ligand (HY-163169); Black: linker (HY-76667)
    SJ11646
  • HY-101034

    CHMFL-ABL-KIT-155

    Bcr-Abl c-Kit Apoptosis PDGFR Discoidin Domain Receptor Cancer
    CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC50s of 46 nM and 75 nM, respectively), and it also presents significant inhibitory activities to BLK (IC50=81 nM), CSF1R (IC50=227 nM), DDR1 (IC50=116 nM), DDR2 (IC50=325 nM), LCK (IC50=12 nM) and PDGFRβ (IC50=80 nM) kinases. CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155) arrests cell cycle progression and induces apoptosis [1].
    CHMFL-ABL/KIT-155
  • HY-150552

    JNK Discoidin Domain Receptor Inflammation/Immunology Cancer
    JNK3 inhibitor-2 is a potent and selective JNK3 inhibitor with IC50 values of >100, >100, 0.25 µM for JNK1, JNK2, JNK3, respectively. JNK3 inhibitor-2 shows DDR1 and EGFR (T790M, L858R) inhibition [1].
    JNK3 inhibitor-2
  • HY-122848

    Discoidin Domain Receptor Inflammation/Immunology
    DDR1/2 inhibitor-3 (5n) is a DDR1/2 inhibitor, with IC50 values​of 9.4 and 20.4 nM, respectively. DDR1/2 inhibitor-3 can be used in anti-inflammatory research [1].
    DDR1/2 inhibitor-3
  • HY-P990400

    Discoidin Domain Receptor Inflammation/Immunology
    Anti-DDR1/CD167a Antibody is a CHO-expressed antibody that targets DDR1/CD167a. The Anti-DDR1/CD167a Antibody has a mouse IgG1 type heavy chain and a mouse κ type light chain, with a predicted molecular weight (MW) of 143.32 kDa. The isotype control for Anti-DDR1/CD167a Antibody can refer to Mouse IgG1 kappa, Isotype Control (HY-P99977).
    Anti-DDR1/CD167a Antibody
  • HY-176186

    PROTAC Linkers Cancer
    4-Hydroxy-1-piperidinepropanamide is a PROTAC linker that can be used in the synthesis of PROTAC DDR1 degrader-1 (HY-176184) [1].
    4-Hydroxy-1-piperidinepropanamide
  • HY-181839

    Discoidin Domain Receptor Inflammation/Immunology
    DDR1/2 IN-4 (Compound 37) is a selective dual DDR1 and DDR2 kinase inhibitor, with a pKi of 8.6 for DDR1 and a pKi of 8.2 for DDR2. DDR1/2 IN-4 functionally inhibits the kinase activities of DDR1 and DDR2. DDR1/2 IN-4 inhibits the release of MCP-1. DDR1/2 IN-4 can be used in studies related to idiopathic pulmonary fibrosis [1].
    DDR1/2 IN-4
  • HY-176188

    E3 Ligase Ligand-Linker Conjugates Cancer
    Lenalidomide-5-Br-amide-C2-Br is an E3 ligase ligand-linker conjugate. Lenalidomide-5-Br-amide-C2-Br can be used to synthesize PROTAC DDR1 degrader-1 (HY-176184) [1].
    Lenalidomide-5-Br-amide-C2-Br
  • HY-181754

    Discoidin Domain Receptor Others
    TPKI-39 is a DDR1, DDR2, and FLT1 inhibitor, with a human DDR1 IC50 of 380 nM, human DDR1 Ka of 24 nM, human DDR2 IC50 of 120 nM, human FLT1 IC50 of 65 nM, and human FLT1 Ka of 91 nM.TPKI-39 inhibits DDR1 enzymatic activity and autophosphorylation, DDR2 enzymatic activity, and FLT1 enzymatic activity in cells.TPKI-39 inhibits collagen-induced DDR1 autophosphorylation in cells [1].
    TPKI-39
  • HY-183068

    NEKs CDK Discoidin Domain Receptor EGFR PI3K Cancer
    AP4-43 is an orally active CLK1, CLK4, PI3K, DDR1, EGFR and NEK4 inhibitor. AP4-43 reduces growth of mammalian colorectal cancer organoids. AP4-43 improves survival in a transgenic Drosophila model of KRAS-mutant colorectal cancer. AP4-43 can be used for the research of KRAS-mutant colorectal cancer [1].
    AP4-43
  • HY-P992066

    Discoidin Domain Receptor Inflammation/Immunology
    Anti-Mouse DDR2 Antibody (DAB0065) is a mAb that specifically targets mouse discoidin domain receptor DDR2 without cross-reacting with DDR1. Anti-Mouse DDR2 Antibody (DAB0065) binds to the extracellular domain of native mouse DDR2, induces endocytosis and lysosomal degradation of DDR2, and this process is independent of collagen binding. Anti-Mouse DDR2 Antibody (DAB0065) exhibits significant therapeutic effects in both the unilateral ureteral obstruction (UUO) mouse model of renal fibrosis and the bleomycin (HY-108345)-induced mouse model of pulmonary fibrosis, effectively downregulating the mRNA expression of type I collagen Col1a1 and fibronectin Fn1. Anti-Mouse DDR2 Antibody (DAB0065) can be humanized and has the potential to be developed as a targeted agent for diseases such as idiopathic pulmonary fibrosis and renal fibrosis [1] .
    Anti-Mouse DDR2 Antibody (DAB0065)
  • HY-179535

    TAM Receptor Discoidin Domain Receptor TGF-β Receptor Hedgehog Cancer
    Axl-IN-21 is an orally active and selective AXL inhibitor (Kd = 2.7 nM, IC50 = 4.0 nM). Axl-IN-21 displays kinase selectivity and retains strong activity against cancer-related mul-kinases (Mer with Kd = 1.4 nM, DDR1 with IC50 = 22.2 nM, HIPK4 with Kd = 11.0 nM and LOK with Kd =10 nM). Axl-IN-21 overcomes tumor microenvironment-driven resistance by blocking CAF-derived GAS6-induced AXL/STAT3/ABCG1 signaling, restoring chemosensitivity and inhibiting drug efflux in gastric cancer (GC). Axl-IN-21 suppresses TGF-β1-induced epithelial-mesenchymal transition (EMT), migration, and invasion in MDA-MB-231 cells. Axl-IN-21 exhibits no significant cytotoxicity in non-cancerous cells. Axl-IN-21 can be research for triple negative breast cancer and gastric cancer [1] [2] .
    Axl-IN-21
  • HY-100115R

    p38 MAPK Reference Standards Autophagy Cardiovascular Disease Inflammation/Immunology Cancer
    TA-02 (Standard) is the analytical standard of TA-02 (HY-100115). This product is intended for research and analytical applications. TA-02, an analog of SB 203580 (HY-10256), is a p38 MAPK inhibitor with an IC50 of 20 nM. TA-02 especially inhibits TGFBR-2. TA-02 exhibits similar cardiogenic properties as SB 203580 and SB 202190 (HY-10295) [1].
    TA-02 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: